The combined effect of permeation enhancement and proteolysis inhibition on the systemic exposure of orally administrated peptides: Salcaprozate sodium, soybean trypsin inhibitor, and teriparatide study in pigs
- PMID: 34704013
- PMCID: PMC8524144
- DOI: 10.1016/j.ijpx.2021.100097
The combined effect of permeation enhancement and proteolysis inhibition on the systemic exposure of orally administrated peptides: Salcaprozate sodium, soybean trypsin inhibitor, and teriparatide study in pigs
Abstract
Oral delivery of peptides and proteins is hindered by their rapid proteolysis in the gastrointestinal tract and their inability to permeate biological membranes. Various drug delivery approaches are being investigated and implemented to overcome these obstacles. In the discussed study conducted in pigs, an investigation was undertaken to assess the effect of combination of a permeation enhancer - salcaprozate sodium, and a proteolysis inhibitor - soybean trypsin inhibitor, on the systemic exposure of the peptide teriparatide, following intraduodenal administration. Results demonstrate that this combination achieves significantly higher Cmax and AUC (~10- and ~20-fold respectively) compared to each of these methodologies on their own. It was thus concluded that an appropriate combination of different technological approaches may considerably contribute to an efficient oral delivery of biological macromolecules.
Keywords: GIT, gastrointestinal tract; Oral delivery; PK, pharmacokinetics; PTH, parathyroid hormone; Permeation enhancer; Pharmacokinetics; SBTI, soybean trypsin inhibitor; SNAC; SNAC, salcaprozate sodium; Salcaprozate sodium; Soybean trypsin inhibitor; Teriparatide; hPTH(1–34), teriparatide.
© 2021 The Author(s).
Conflict of interest statement
None.
Figures
References
-
- Aguirre T.A., Teijeiro-Osorio D., Rosa M., Coulter I.S., Alonso M.J., Brayden D.J. Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. Adv. Drug Deliv. Rev. 2016;106(Pt B):223–241. doi: 10.1016/j.addr.2016.02.004. https://www.ncbi.nlm.nih.gov/pubmed/26921819 - DOI - PubMed
-
- Alani A.W., Robinson J.R. Mechanistic understanding of oral drug absorption enhancement of cromolyn sodium by an amino acid derivative. Pharm. Res. 2008;25(1):48–54. doi: 10.1007/s11095-007-9438-6. https://www.ncbi.nlm.nih.gov/pubmed/17846867 - DOI - PubMed
-
- Animals, National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory . 2011. Guide for the Care and Use of Laboratory Animals.
-
- Birk Y. Trypsin and chymotrypsin inhibitors from soybeans. Methods Enzymol. 1976;45:700–707. doi: 10.1016/s0076-6879(76)45061-9. https://www.ncbi.nlm.nih.gov/pubmed/1034864 - DOI - PubMed
-
- Brayden D., Creed E., O’Connell A., Leipold H., Agarwal R., Leone-Bay A. Heparin absorption across the intestine: effects of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate in rat in situ intestinal instillations and in Caco-2 monolayers. Pharm. Res. 1997;14(12):1772–1779. doi: 10.1023/a:1012192115828. https://www.ncbi.nlm.nih.gov/pubmed/9453067 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
